Literature DB >> 9681098

Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial.

E I Ette1.   

Abstract

OBJECTIVE: To discuss the use of statistical graphics in the analysis of pharmacokinetics and pharmacodynamics data.
METHODS: Information on graphic techniques and their application was retrieved from a MEDLINE search (January 1980-March 1997) of the English-language literature and bibliographic reviews of review articles and books. Data used to generate plots were extracted from some new drug applications submitted to the Food and Drug Administration and by simulation. DATA SYNTHESIS: In carrying out data analysis, we should look at data in several ways, construct a number of plots, and do several analyses, letting the results of each step suggest the next. The information from a plot should be relevant to the goals of the analysis. Thus, in choosing a graphic method, it is necessary to match the capabilities of the method to the need in the context of the application. For example, if linear relationships among variables in a set of multidimensional data are relevant, scatter plots such as the pairs plot with smoothing is likely to be more informative than other graphic methods. It is necessary to recognize what kinds of perceived structure are attributable to the data, and what kinds are artifacts of the display technique itself when using graphs for data analysis.
CONCLUSIONS: Graphic techniques enable the data analyst to explore data thoroughly, look for patterns and relationships, confirm or disprove the expected, and discover new phenomena. An important element of statistical graphic techniques is flexibility, both in tailoring the analysis to the structure of the data and in responding to patterns that successive steps of analysis uncover. Statistical graphics can and should be used to enhance numeric statistical analyses.

Mesh:

Year:  1998        PMID: 9681098     DOI: 10.1345/aph.17304

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

Review 3.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

4.  Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures.

Authors:  Marcel P H van den Broek; Alwin D R Huitema; Johan G C van Hasselt; Floris Groenendaal; Mona C Toet; Toine C G Egberts; Linda S de Vries; Catharine M A Rademaker
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

5.  Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

Authors:  Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri H Roché; Jean-Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

6.  Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.

Authors:  Géraldine M Ferron; Yang Dai; Dorothée Semiond
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-09       Impact factor: 3.333

7.  Development of an optimal lidocaine infusion strategy for neonatal seizures.

Authors:  Mirte M Malingré; Linda G M Van Rooij; Carin M A Rademaker; Mona C Toet; Tessa F F T Ververs; Charlotte van Kesteren; Linda S de Vries
Journal:  Eur J Pediatr       Date:  2006-05-12       Impact factor: 3.183

8.  Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.

Authors:  Trudy D Buitenkamp; Ron A A Mathôt; Valerie de Haas; Rob Pieters; C Michel Zwaan
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

9.  PKreport: report generation for checking population pharmacokinetic model assumptions.

Authors:  Xiaoyong Sun; Jun Li
Journal:  BMC Med Inform Decis Mak       Date:  2011-05-16       Impact factor: 2.796

10.  Exploring population pharmacokinetic modeling with resampling visualization.

Authors:  Fenghua Zuo; Jun Li; Xiaoyong Sun
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.